The US Food and Drug Administration (FDA) on Thursday approved the first medication for people with a severe type of non-alcoholic fatty liver disease.

Madrigal Pharmaceuticals’ Rezdiffra was shown to improve liver scarring in a clinical trial involving hundreds of people with non-alcoholic steatohepatitis (NASH), the worst form of the condition caused by a buildup of fat in the liver.

“Previously, patients with NASH who also have notable liver scarring did not have a medication that could directly address their liver damage,” said the FDA’s Nikolay Nikolov.

“Today’s approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise.”

      • ThoGot
        link
        fedilink
        English
        arrow-up
        3
        arrow-down
        1
        ·
        3 months ago

        and also probably high consumption of fructose

        • GBU_28
          link
          fedilink
          English
          arrow-up
          3
          ·
          3 months ago

          That’s a cause of the above conditions

    • autumn_rain@lemmy.world
      link
      fedilink
      English
      arrow-up
      1
      ·
      edit-2
      3 months ago

      Thyroid disorders cause high cholesterol and can cause non-alcoholic fatty liver disease because it’s unable to process cholesterol effectively. A person can have fatty liver and be active and thin, don’t eat sugar, junk food, drink, etc.

      Edit… also just because someone is taking thyroid medicine, the cholesterol issue doesn’t always resolve.